TY - JOUR
T1 - Insulin pump therapy management in very young children with type 1 diabetes using continuous subcutaneous insulin infusion
AU - Rabbone, Ivana
AU - Scaramuzza, Andrea
AU - Bobbio, Adriana
AU - Bonfanti, Riccardo
AU - Iafusco, Dario
AU - Lombardo, Fortunato
AU - Toni, Sonia
AU - Tumini, Stefano
AU - Cerutti, Franco
PY - 2009/11/1
Y1 - 2009/11/1
N2 - Background: Compared to older children and adolescents very young patients with type 1 diabetes represent a unique population. We analyzed the age-dependent characteristics and parameters of continuous subcutaneous insulin infusion (CSII) in children under 6 years of age with type 1 diabetes. Methods: We evaluated metabolic control and pump-dependent characteristics in 46 children with type 1 diabetes after 0.89 ± 0.62 years of CSII. Results: Metabolic control significantly improved after CSII initiation (glycosylated hemoglobin, 8.12 ± 1.24% vs. 7.30 ± 0.67%; P < 0.05), without increased risk for diabetic ketoacidosis or hypoglycemia. Interestingly, very young patients required bigger boluses than expected, especially in the morning and at the afternoon snack. Conclusions: These data support the need to personalize pump-dependent characteristics, especially in very young children with type 1 diabetes, in order to optimize CSII therapy in this unique age group of patients.
AB - Background: Compared to older children and adolescents very young patients with type 1 diabetes represent a unique population. We analyzed the age-dependent characteristics and parameters of continuous subcutaneous insulin infusion (CSII) in children under 6 years of age with type 1 diabetes. Methods: We evaluated metabolic control and pump-dependent characteristics in 46 children with type 1 diabetes after 0.89 ± 0.62 years of CSII. Results: Metabolic control significantly improved after CSII initiation (glycosylated hemoglobin, 8.12 ± 1.24% vs. 7.30 ± 0.67%; P < 0.05), without increased risk for diabetic ketoacidosis or hypoglycemia. Interestingly, very young patients required bigger boluses than expected, especially in the morning and at the afternoon snack. Conclusions: These data support the need to personalize pump-dependent characteristics, especially in very young children with type 1 diabetes, in order to optimize CSII therapy in this unique age group of patients.
UR - http://www.scopus.com/inward/record.url?scp=70449646695&partnerID=8YFLogxK
U2 - 10.1089/dia.2009.0064
DO - 10.1089/dia.2009.0064
M3 - Article
SN - 1520-9156
VL - 11
SP - 707
EP - 709
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 11
ER -